Regenerative medicine as a novel strategy for AMD treatment: a review

Biomed Phys Eng Express. 2019 Nov 13;6(1):012001. doi: 10.1088/2057-1976/ab269a.

Abstract

Age-related macular degeneration (AMD) is known as a major cause of irreversible blindness in elderly adults. The segment of the retina responsible for central vision damages in the disease process. Degeneration of retinal pigmented epithelium (RPE) cells, photoreceptors, and choriocapillaris associated with aging participate for visual loss. In 2010, AMD involved 6.6% of all blindness cases around the world. Some of the researches have evaluated the replacing of damaged RPE in AMD patients by using the cells from various sources. Today, the advancement of RPE differentiation or generation from stem cells has been gained, and currently, clinical trials are testing the efficiency and safety of replacing degenerated RPE with healthy RPE. However, the therapeutic success of RPE transplantation may be restricted unless the transplanted cells can be adhered, distributed and survive for long-term in the transplanted site without any infections. In recent years a variety of scaffold types were used as a carrier for RPE transplantation and AMD treatment. In this review, we have discussed types of scaffolds; natural or synthetic, solid or hydrogel and their results in RPE replacement. Eventually, our aim is highlighting the novel and best scaffold carriers that may have potentially promoting the efficacy of RPE transplantation.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Macular Degeneration / pathology
  • Macular Degeneration / therapy*
  • Male
  • Regenerative Medicine / methods*
  • Retina / pathology
  • Retinal Pigment Epithelium / pathology
  • Retinal Pigment Epithelium / transplantation
  • Stem Cell Transplantation